Tags

Type your tag names separated by a space and hit enter

A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
Addict Biol. 2013 Nov; 18(6):993-1002.AB

Abstract

Marijuana withdrawal contributes to the high relapse rates in individuals seeking treatment for marijuana-use disorders. Quetiapine, an atypical antipsychotic, reduces characteristic symptoms of marijuana withdrawal in a variety of psychiatric conditions, including mood lability, sleep disruption and anorexia. This human laboratory study investigated the effectiveness of quetiapine to decrease marijuana withdrawal and relapse to marijuana use in non-treatment-seeking marijuana smokers. Volunteers were maintained on placebo or quetiapine (200 mg/day) in this double-blind, counter-balanced, within-subject study consisting of two 15-day medication phases, the last 8 days of which were in-patient. On the first in-patient day, active marijuana [6.2% delta (9)-tetrahydrocannabinol (THC)] was repeatedly smoked under controlled conditions. For the next 3 days, inactive marijuana (0.0% THC) was available for self-administration (withdrawal). On the subsequent 4 days, active marijuana (6.2% THC) was available for self-administration (relapse). Volunteers (n = 14) who smoked an average of 10 marijuana cigarettes/day, 7 days/week, completed the study. Under placebo, withdrawal was marked by increased subjective ratings of negative mood, decreased sleep quality, and decreased caloric intake and weight loss. Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss. However, quetiapine increased marijuana craving and marijuana self-administration during the relapse phase. These data do not suggest that quetiapine shows promise as a potential treatment for marijuana dependence.

Authors+Show Affiliations

Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

22741619

Citation

Cooper, Ziva D., et al. "A Human Laboratory Study Investigating the Effects of Quetiapine On Marijuana Withdrawal and Relapse in Daily Marijuana Smokers." Addiction Biology, vol. 18, no. 6, 2013, pp. 993-1002.
Cooper ZD, Foltin RW, Hart CL, et al. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol. 2013;18(6):993-1002.
Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M. (2013). A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addiction Biology, 18(6), 993-1002. https://doi.org/10.1111/j.1369-1600.2012.00461.x
Cooper ZD, et al. A Human Laboratory Study Investigating the Effects of Quetiapine On Marijuana Withdrawal and Relapse in Daily Marijuana Smokers. Addict Biol. 2013;18(6):993-1002. PubMed PMID: 22741619.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. AU - Cooper,Ziva D, AU - Foltin,Richard W, AU - Hart,Carl L, AU - Vosburg,Suzanne K, AU - Comer,Sandra D, AU - Haney,Margaret, Y1 - 2012/06/28/ PY - 2012/6/30/entrez PY - 2012/6/30/pubmed PY - 2014/8/5/medline KW - Marijuana KW - relapse KW - withdrawal SP - 993 EP - 1002 JF - Addiction biology JO - Addict Biol VL - 18 IS - 6 N2 - Marijuana withdrawal contributes to the high relapse rates in individuals seeking treatment for marijuana-use disorders. Quetiapine, an atypical antipsychotic, reduces characteristic symptoms of marijuana withdrawal in a variety of psychiatric conditions, including mood lability, sleep disruption and anorexia. This human laboratory study investigated the effectiveness of quetiapine to decrease marijuana withdrawal and relapse to marijuana use in non-treatment-seeking marijuana smokers. Volunteers were maintained on placebo or quetiapine (200 mg/day) in this double-blind, counter-balanced, within-subject study consisting of two 15-day medication phases, the last 8 days of which were in-patient. On the first in-patient day, active marijuana [6.2% delta (9)-tetrahydrocannabinol (THC)] was repeatedly smoked under controlled conditions. For the next 3 days, inactive marijuana (0.0% THC) was available for self-administration (withdrawal). On the subsequent 4 days, active marijuana (6.2% THC) was available for self-administration (relapse). Volunteers (n = 14) who smoked an average of 10 marijuana cigarettes/day, 7 days/week, completed the study. Under placebo, withdrawal was marked by increased subjective ratings of negative mood, decreased sleep quality, and decreased caloric intake and weight loss. Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss. However, quetiapine increased marijuana craving and marijuana self-administration during the relapse phase. These data do not suggest that quetiapine shows promise as a potential treatment for marijuana dependence. SN - 1369-1600 UR - https://www.unboundmedicine.com/medline/citation/22741619/A_human_laboratory_study_investigating_the_effects_of_quetiapine_on_marijuana_withdrawal_and_relapse_in_daily_marijuana_smokers_ L2 - https://doi.org/10.1111/j.1369-1600.2012.00461.x DB - PRIME DP - Unbound Medicine ER -